Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Alpharen in haemodialysis patients with hyperphosphataemia
2005-005746-39Phase 2Completed
- Sponsor
- INEOS Healthcare Limited
- Start
- Dec 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sevelamer carbonate in hyperphosphatemia (2 arms), sponsored by INEOS Healthcare Limited. Primary endpoint: Proportion of subjects achieving controlled serum phosphate concentrations. Started Dec 2005; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on 2005-005746-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005746-39.